In this talk participants will learn how they can spin out their research into a biotech company without having to leave their academic research behind.
Professor Hans Stauss, Director, Institute of Immunity and Transplantation, UCL.
Professor Hans Stauss was an early trail blazer in the field of cancer immunotherapy demonstrating how modified T cells could be used to effectively target tumours. Recognising the medical potential of this research Hans was involved in setting up Cell Medica which is now advancing an impressive pallet of innovative proprietary technologies in the field of immune cell therapy for cancer and viral infections. Meanwhile Hans continues to turn out cutting edge research and is involved in a number of clinical trials.